Interpace Biosciences Inc. (NASDAQ: IDXG) Starts Presentation at NobleCon16
Interpace Biosciences (NASDAQ: IDXG) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The company’s Interpace Diagnostics subsidiary provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer. Its Interpace Pharma Solutions subsidiary provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Interpace has four commercialized molecular tests and one test in a clinical evaluation process: PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid…







